in patients with congenital adrenal hyperplasia. Plasma 17-hydroxyprogesterone (17-OHP) levels in 4 patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency were greatly raised and showed a marked circadian variation, with high morning levels and much lower values during the late evening. This finding indicates that patients with CAH may require relatively little adrenal suppression during the late evening and early hours of sleep, and suggests that the main suppressive dose of steroid should be reserved for the period between 3.00 a.m. and 3.00 p.m.
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In the majority of patients with congenital adrenal hyperplasia (CAH), the defect in steroid biosynthesis appears to be due to deficiency of 21-hydroxylase, an enzyme necessary for conversion of 17-hydroxyprogesterone (17-OHP) to 11-desoxycortisol. As a result of this deficiency, excessive amounts of 17-OHP are secreted by the adrenal glands and the plasma levels of 17-OHP in children with CAH may be 50-200 times higher than the values found in normal men (Strott, Yoshimi, and Lipsett, 1969) . This paper describes results obtained in 4 patients with CAH which indicate that there is marked circadian variation in plasma 17-OHP in this condition.
Patients and Methods
Patients. Four patients with CAH due to 21-hydroxylase deficiency were studied. The first (Case 1), a boy aged 4 years with the simple virilizing form of the disorder, was investigated before any treatment was begun. Two other patients who were not salt-losers were studied 3 days after treatment had been temporarily discontinued. One was a 14-year-old boy (Case 2) who had been treated with steroids since the age of 6. He had received 5 mg prednisone twice daily for several months before the period of investigation and his urinary 17-oxosteroid excretion had ranged from 7-7 mg/24 hr to 9 3 mg/24 hr on this treatment. The other was a 16-year-old girl (Case 3) who had been treated since the age of 1 year. Before investigation she had received 7 -5 mg cortisone acetate three times a day and the levels of her urinary 17-oxosteroids lay between 6x5 mg/24 hr and 7x6 mg/24 hr. The fourth patient (Case 4), an 18-year-old girl with the salt-losing form of the disorder, was investigated while receiving 25 mg cortisone acetate every 6 hours. Before the period of investigation she had been treated with 50 mg cortisone acetate twice daily and though she showed no gross evidence of virilization, her persistent amenorrhoea suggested that her adrenal hyperplasia was poorly controlled. Her urinary 17-oxosteroid excretion was 26 -4 mg/24 hr.
Methods. Venous blood samples were obtained at 11.00 p.m. and 9.30 a.m. in Case 1. Serial blood samples were obtained at roughly 2-hour intervals for 24 hours in the other 3 patients, using an indwelling intravenous catheter.
Plasma 17-OHP was estimated by a simple proteinbinding technique (Barnes and Atherden, 1972 ) based on the method of Murphy (1967) . Plasma samples were extracted with 2% ethanol in petroleum ether. Tritiated cortisol and dilute human plasma (CBG) were used to estimate the 17-OHP extracted. Using 0 05 ml volumes of plasma, the lower limit of sensitivity of the assay is 0 5 ,ug/100 ml plasma and the assay is insufficiently sensitive to detect the low levels of plasma 17-OHP found in normal subjects (Strott et al., 1969; Abraham et al., 1971) . Details of the precision of the assay have been given elsewhere (Barnes and Atherden, 1972 ).
The method is not specific for 17-OHP as progesterone is also extracted from plasma. However, as progesterone shows only a 40% competition for CBG when compared with 17-OHP, and as the plasma progesterone concentration is only about 3-13% of that of 17-OHP in CAH (Strott et al., 1969; Simopoulos etal., 1971) , the errors caused by this lack of specificity are likely to be small in patients with this condition.
Results
The results obtained in Case 1 before treatment was started are given in the Table. The plasma 17-OHP level at 11.00 p.m. was 0 7 Cug/100 ml, but a second specimen taken at 9.30 a.m. the following morning gave a value of 13 * 8 [±g/100 ml. (Graber et al., 1965; Besser et al., 1971) , and in normal subjects after blockade of cortisol biosynthesis by the 1 1-hydroxylase inhibitor, metyrapone (Jubiz et al., 1970) .
We have recently tried to determine whether estimation of plasma 17-OHP can be of value in assessing treatment in patients with CAH (Barnes and Atherden, 1972 (Nichols, Nugent, and Tyler, 1965) , and late night treatment of patients with CAH may permit the use of smaller doses of steroid (Hayek, Crawford, and Bode, 1971 ). Whether such timing of treatment can reduce the risks of steroid-induced growth retardation is still unknown. The results obtained with alternate-day steroid therapy in children with the nephrotic syndrome (Soyka, 1967) indicate that growth suppression is not solely dependent on steroid dose but may also be related to the daily timing of treatment.
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